MedTrace Logo

Hepatitis C Treatment in Underserved Populations

NCT01717560 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-10-30

No results posted yet for this study

Summary

The purpose of this study is to examine the feasibility, safety, and effectiveness of treating persons who are actively using illicit drugs for hepatitis C using a collaborative, multidisciplinary, integrated care model. We hypothesize that by maximizing facilitators and minimizing barriers to treatment we can enable drug users to receive effective treatment for hepatitis C.

Conditions

  • Chronic Hepatitis C
  • Illicit Drug Use

Interventions

OTHER

Collaborative, multidisciplinary, integrated care

Collaborative, multidisciplinary, integrated care for hepatitis C multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management.

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    collaborator OTHER

  • State University of New York - Downstate Medical Center

    collaborator OTHER

  • Brian Edlin

    lead OTHER

Principal Investigators

  • Brian R. Edlin, MD · Weill Medical College, Cornell University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2012-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717560 on ClinicalTrials.gov